Dept Menu

Audience Menu

 
Assessing acceptability, benefits and satisfaction with the levonorgestrel-containing intrauterine system as a contraceptive method for women initiating chemotherapy

Melody Hou, MD MPH, University of California, Davis School of Medicine

Project abstract

Reproductive health, including contraception, is a neglected area of healthcare for women initiating chemotherapy for newly diagnosed malignancies. Lymphoma and leukemia are particularly prominent among young women who are interested in future fertility. Progestin intrauterine contraception can provide a huge benefit for contraception, and may have additional benefit by preventing chemotherapy-induced thrombocytopenia-associated menorrhagia that would otherwise have a significant negative impact on quality of life during this vulnerable time.

We propose a retrospective case series to evaluate what contraceptive counseling was provided by hematologist-oncologists to women beginning chemotherapy for malignancies and a concurrent prospective pilot study to assess the acceptability and bleeding pattern of the levonorgestrel intrauterine device in women beginning chemotherapy.


Back to top